ACTG1 and neoplasm: ACTG1 levels in the wider patient population, as measured by ELISA, did not differ when pre-treatment and four weeks post-treatment were compared, or by tumour grade or tumour strata; there was also no difference in PFS by pre-treatment ACTG1 expression (supplementary appendix 6, figure S6b).